Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.

Overview
Research
Identity
Additional Document Info
View All

authors

Jingran Ji, MD
Mitra, Anupam
Camidge, D Ross
Riess, Jonathan W

publication date

January 1, 2021

published in

Clinical lung cancer Journal

has subject area